Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities.

Autor: Lisa Ross, Michael Lim, Qiming Liao, Brian Wine, Allan Rodriguez, Winkler Weinberg, Mark Shaefer
Zdroj: HIV Clinical Trials; Jan2007, Vol. 8 Issue 1, p1-8, 8p
Abstrakt: Background: Transmission of drug-resistant HIV strains to antiretroviral therapy (ART)-naïve subjects can negatively impact therapy response. As treatment strategies and utilization of antiretroviral drugs evolve, patterns of transmitted mutations may shift. Method: Paired genotypic and phenotypic susceptibility data were retrospectively analyzed for 317 ART-naïve, HIV—infected subjects from 40 small and major metropolitan cities in the Northeastern, Midwestern, Southern, Southwestern, and Northwestern United States during 2003. Results: Using current (January 2007) PhenoSense cutoffs, HIV-from 8% of subjects had reduced susceptibility to ⩾1 drug. By class, >% had reduced susceptibility to protease inhibitors (PIs), and % had reduced susceptibility to nucleoside reverse transcriptase inhibitors (NRTIs); reduced susceptibility to ⩾1 non-nucleoside reverse transcriptase inhibitor (NNRTIs) was seen in 7% of subjects, with 4% of all subjects having reduced susceptibility to all NNRTIs. IAS-USA–defined NRTI, NNRTI, and/or major PI HIV-drug resistance–associated mutations were detected for 0% of the subjects. HIV risk factors included homosexual contact (74%), heterosexual contact (28%), and injectable drug use/transfusion/other (7%). Reduced susceptibility to ⩾1 drug was significantly higher (p = .034) for white subjects than African Americans and Hispanics/others. Conclusion: The high prevalence of drug resistance in these ART-naïve subjects suggests that transmitted resistance is occurring widely within the United States. HIV genotyping and/or phenotyping for antiretroviral-naïve patients seeking treatment should be considered, especially if the therapy will include an NNRTI. [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index